Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

78.71 -0.69 (-0.87%)

Streaming Delayed Price Updated: 11:25 AM EST, Dec 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Via Benzinga

Topics ETFs

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗

September 29, 2025

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.

Via Benzinga

1 Momentum Stock with Competitive Advantages and 2 We Find Risky

September 26, 2025

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or...

Via StockStory

What Analysts Are Saying About Corcept Therapeutics Stock ↗

September 25, 2025

Throughout the last three months, 4 analysts have evaluated Corcept Therapeutics (NASDAQ: CORT), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent...

Via Benzinga

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Why Are Corcept (CORT) Shares Soaring Today

September 23, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 5.4% in the afternoon session after the company announced it would present new data from its pivotal Phase 3 ROSELLA trial and that...

Via StockStory

Topics Artificial Intelligence

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025

September 22, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment

September 15, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Corcept (NASDAQ:CORT) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

September 10, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

3 Cash-Producing Stocks That Concern Us

September 09, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) Embodies the "Affordable Growth" Investment Strategy ↗

August 20, 2025

Discover Corcept Therapeutics (CORT), an affordable growth stock with strong revenue growth, high profitability, and a compelling valuation within the pharmaceuticals sector.

Via Chartmill

Corcept Therapeutics Inc (NASDAQ:CORT): A Strong Growth Stock with Solid Fundamentals and Technical Upside ↗

August 18, 2025

Corcept Therapeutics (CORT) shows strong growth, profitability, and technical momentum, making it a top pick for investors seeking high-potential stocks.

Via Chartmill

3 Cash-Heavy Stocks with Warning Signs

August 18, 2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

Via StockStory

CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook

August 13, 2025

Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 18.7% year on year to $194.4 million. The company’s full-year revenue...

Via StockStory

2 Growth Stocks Set to Flourishand 1 We Avoid

August 12, 2025

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Via StockStory

3 Low-Volatility Stocks That Fall Short

August 04, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗

August 01, 2025

Via Benzinga

Corcept (NASDAQ:CORT) Misses Q2 Sales Targets

July 31, 2025

Via StockStory

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

July 31, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

CORCEPT THERAPEUTICS INC (NASDAQ:CORT): A Strong Affordable Growth Pick with Solid Fundamentals ↗

July 30, 2025

CORCEPT THERAPEUTICS (CORT) offers strong growth potential with fair valuations, solid profitability, and a healthy balance sheet, making it an attractive pick for Affordable Growth investors.

Via Chartmill

What To Expect From Corcept’s (CORT) Q2 Earnings

July 29, 2025

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be reporting earnings this Thursday after the bell. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

July 24, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential ↗

July 22, 2025

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shows strong revenue growth, high profitability, and a promising technical setup, making it a noteworthy candidate for growth investors.

Via Chartmill

Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years ↗

July 21, 2025

Via Benzinga

agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know

July 18, 2025

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like...

Via StockStory

Topics Lawsuit World Trade

What's Driving the Market Sentiment Around Corcept Therapeutics? ↗

July 17, 2025

Via Benzinga

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

July 14, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

3 High-Flying Stocks Skating on Thin Ice

July 14, 2025

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Via StockStory

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - A Promising Affordable Growth Stock ↗

July 09, 2025

CORCEPT THERAPEUTICS (NASDAQ:CORT) offers strong growth, solid profitability, and reasonable valuation, making it an interesting candidate for investors seeking affordable growth stocks.

Via Chartmill

1 Cash-Producing Stock Worth Your Attention and 2 to Ignore

July 07, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.